The Heifets Laboratory
Welcome to the Heifets Lab
Our research group is dedicated to understanding and improving on powerful, rapid-acting therapies for psychiatric disease, such as ketamine, MDMA and psilocybin. We bridge basic science and clinical trials, connecting neuroscience, psychiatry and anesthesiology in pursuit of highly effective, safe treatment strategies scalable to the millions of patients who need them.
Follow Us on Twitter
Recruiting for #OCDresearch at Stanford
Stanford Medicine is enrolling adults ages 18–65 with #OCD for a research study examining ketamine’s effects on the brain.
💰 Up to $450 compensation
📍 Stanford University
📧 ocdresearch@stanford.edu
🔗 http://med.stanford.edu/ocd-research/research.html
🔍 Another “novel pain drug” using Von Frey test only, P>0.001 with n=5 mice and incredibly tight sem bars shown in opposite direction from control group
The Brain Never Sleeps : Chapter 9 - The Power of Big Dreams - all about Stanford dream anesthesia research!
That anesthesia dreams can be induced , monitored, documented like an X-Ray and maybe transformational - with hard research to prove that underway. Congrats research
Quick thoughts on the new COMPASS phase 3 topline results ():
- After 2 high doses (25mg) of #psilocybin, a 3.8 points difference on the MADRS from placebo (1mg psilocybin)? Underwhelming, despite stat significance. Why? Because this ~4 points difference is
Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360...
Two highly statistically significant positive Phase 3 trials confirm highly differentiated profile for COMP360, demonstrat...
tinyurl.com
Since everyone is abuzz with their opinions on cannabis today, seems timely to repost this. Despite the fact that @hubermanlab and I come from different perspectives on this, I think this is a pretty thorough (4h!!) and balanced discussion (with over 20 min on psychosis alone).
Top 4 questions for psychedelic medicine in 2026:
1. What’s the neurobiology of psychedelic experiences?
2. Is the experience necessary for clinical benefit?
3. How do we solve expectancy + unblinding in trials?
4. What does safe scaling actually look like?
We synthesize what
I got to work with a psychedelic dream team on this! @RCarhartHarris, Conor Liston, Ginger Nicol, and Michael Bogenschutz
Very proud of what came out of it - - a rigorous, insightful, and authoritative review IMHO
New Review: The science of #psychedelic medicine.
Joshua Siegel & colleagues integrate mechanistic knowledge with clinical evidence across neuropsychiatric indications — highlighting challenges, controversies, and opportunities.
@realJoshSiegel @RCarhartHarris @nyugrossman
DMT neurochemistry and neurophysiology in the rat brain: Journal of Neuroscience article now published based on work of Nick Glynos, Emma Huels, Dinesh Pal and others from the Michigan Psychedelic Center. https://www.jneurosci.org/content/46/5/e0742242025
